Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.57 |
| ▸ | CCR2 | P41597 | 12/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881352 | 0.88 | GPR35 (0.43) | GPR35ALDH1A1POLBKDM4EHPGD | |
| SCHEMBL9613336 | 0.83 | CCR2 (0.41) | GPR35CCR2ALDH1A1POLBCYP1A2 | |
| SCHEMBL9613261 | 0.83 | PTGES (0.47) | GPR35CCR2ALDH1A1POLBCYP1A2 | |
| SCHEMBL9613218 | 0.82 | CCR2 (0.39) | GPR35CCR2ALDH1A1POLBCYP1A2 | |
| SCHEMBL17648927 | 0.80 | CCR2 (0.48) | GPR35CCR2ALDH1A1ABCB11 | |
| SCHEMBL9613337 | 0.80 | GPR35 (0.62) | GPR35CCR2ALDH1A1POLBCYP1A2 | |
| SCHEMBL9613270 | 0.80 | HSD17B10 (0.62) | GPR35ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL1553069 | 0.80 | GPR35 (0.67) | GPR35CCR2ALDH1A1POLBCYP1A2 | |
| SCHEMBL30790917 | 0.80 | HSD17B10 (0.62) | GPR35ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL22479058 | 0.80 | GRIK1 (0.37) | GPR35ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727797-B1 | PROCESS FOR CROSS COUPLING INDOLES | BOEHRINGER INGELHEIM PHARMA (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| EP-1891951-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | GPR35 2444/4885CCR2 400/4885ALDH1A1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.